{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:06:23Z","timestamp":1794575183249,"version":"4.9.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BJC Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Radiological response evaluation metrics such as RECIST 1.1 inform critical endpoints in oncology trials. The UK was the 6th highest recruiter into oncology trials worldwide between 1999 and 2022, with almost 9000 oncology trials registered during the same period. However, the provision of tumour measurements for oncology trials is often ad hoc and patchy across the NHS. The aim of this work was to understand the barriers to providing an effective imaging tumour measurement service, gain insight into service delivery models and consider the successes and challenges from the perspective of both service providers and end users.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>An electronic survey was distributed to those who provide tumour measurement response review for clinical trials (service providers) and those that request and use such measurements in trial activities (service users).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Responses from 35 sites demonstrated substantial variation in service provision across the UK. Despite workforce pressures, service is largely delivered through radiologists with a minority utilising radiographer role extension. Only 20% of the service providers had dedicated training and 29% received robust financial reimbursement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>Service variation is likely a consequence of limited training, education and infrastructure to support robust service, compounded by increasing radiology workload and workforce pressures.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s44276-025-00131-8","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:46:20Z","timestamp":1743122780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tumour measurements on imaging for clinical trial: A national picture of service provision"],"prefix":"10.1038","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4967-8886","authenticated-orcid":false,"given":"Georgina","family":"Hopkinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Wadsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Darekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Messiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dow-Mu","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"131_CR1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"E Eisenhauer","year":"2019","unstructured":"Eisenhauer E, Therasseb J, Bogaertsc LH, Schwartzd D, SargenteR, Fordf J, et al. \u2018New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)\u2019. Eur J Cancer. 2019;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"131_CR2","doi-asserted-by":"publisher","unstructured":"Bogaerts J, 2015, Perspectives from the RECIST committee on what constitutes a good tumour response metric\u2019 ANNUALS OF ONCOLOGY Abstracts plenary session 9: Beyond RECIST: Novel approaches for evaluating tumour response to molecular targeted agents: Vol 26, Supplement 2. II 13, March 2015 https:\/\/doi.org\/10.1093\/annonc\/mdv087.1","DOI":"10.1093\/annonc\/mdv087.1"},{"key":"131_CR3","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143\u2013152. https:\/\/doi.org\/10.1016\/S1470-2045(17)30074-8","journal-title":"Lancet Oncol"},{"key":"131_CR4","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.jtho.2018.04.034","volume":"13","author":"S Armato","year":"2018","unstructured":"Armato S, Nowak A. Revised modified response evaluation criteria in Solid tumours for assessment of response in malignant pleural mesothelioma (Version 1.1). J Thorac Oncol. 2018;13:1012\u201321.","journal-title":"J Thorac Oncol"},{"key":"131_CR5","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","volume":"25","author":"H Choi","year":"2007","unstructured":"Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753\u20139.","journal-title":"J Clin Oncol"},{"key":"131_CR6","doi-asserted-by":"crossref","unstructured":"McErlean A, Panicek D, Zabor E, Moskowitz C, Bitar R, Motzer R, et al. Intra- and Interobserver Variability in CT Measurements in Oncology, Radiology: Volume 269: Number 2\u2014November 2013 n radiology.rsna.org","DOI":"10.1148\/radiol.13122665"},{"key":"131_CR7","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1007\/s00330-018-5393-3","volume":"28","author":"F Tovoli","year":"2018","unstructured":"Tovoli F, Renzulli M, Negrini G, Brochhi S, Ferrarini A, Andreaone A, et al. Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib. Eur Radio. 2018;28:3611\u201320. https:\/\/doi.org\/10.1007\/s00330-018-5393-3","journal-title":"Eur Radio"},{"key":"131_CR8","unstructured":"The Royal College of Radiologists, Clinical Radiology UK workforce census 2020 report, London, The RCR, 2021, Clinical radiology UK workforce census 2020 report. (rcr.ac.uk)"},{"key":"131_CR9","unstructured":"World Health Organisation, 2023, Health topics: Cancer, WHO Cancer (who.int), accessed 11.01.2024"},{"key":"131_CR10","unstructured":"Department of Health & Social Care, Department for Science, Innovation and Technology and Office for Life Science, Commercial clinical trials in the UK: the Lord O\u2019Shaughnessy review\u2019 May 2023, Commercial clinical trials in the UK: the Lord O\u2019Shaughnessy review - GOV.UK. (www.gov.uk)"},{"key":"131_CR11","unstructured":"Department of Health and Social Care, Plociy paper: The future of Clinical research delivery: 2022 to 2024 implementation plan\u2019 June 2022, https:\/\/www.gov.uk\/government\/publications\/the-future-of-uk-clinical-research-delivery-2022-to-2025-implementation-plan\/the-future-of-clinical-research-delivery-2022-to-2025-implementation-plan#a-sustainable-and-supported-research-workforce"},{"key":"131_CR12","unstructured":"National institute for Health and Care Research, Schedule of Events Costs Attribution template, Schedule of Events Cost Attribution Template (SoECAT) & Excess Treatment Costs (ETCs). (nihr.ac.uk)"},{"key":"131_CR13","first-page":"25","volume":"564","author":"G Hopkinson","year":"2022","unstructured":"Hopkinson G, Taylor J, Metherall P, Johnston E, Sugden J, Messiou C. Response assessment in oncology trials: A Radiographer RECIST service. RAD Mag. 2022;564:25\u20136.","journal-title":"RAD Mag"},{"key":"131_CR14","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.crad.2004.07.012","volume":"60","author":"S Brealey","year":"2005","unstructured":"Brealey S, Scally A, Hahn S, Thomas N, Godfrey C, Coomarasamy A. Accuracy of radiographer plain radiograph reporting in clinical practice: a meta-analysis. Clin Radiol. 2005;60:232\u201341.","journal-title":"Clin Radiol"},{"key":"131_CR15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.radi.2019.09.001","volume":"26","author":"P Lockwood","year":"2020","unstructured":"Lockwood P. An evaluation of CT head reporting radiographers\u2019 scope of practice within the United Kingdom\u2019. Radiography. 2020;26:102\u20139.","journal-title":"Radiography"},{"key":"131_CR16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.radi.2018.01.009","volume":"24","author":"N Woznitza","year":"2018","unstructured":"Woznitza N, Piper K, Burke S, Ellis S, Bothamley S. Agreement between expert thoracic radiologists and the chest radiograph reports provided by consultant radiologists and reporting radiographers in clinical practice: Review of a single clinical site\u2019. Radiography. 2018;24:234\u20139.","journal-title":"Radiography"},{"key":"131_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ejrad.2019.07.030","volume":"118","author":"H Beaumont","year":"2019","unstructured":"Beaumont H, Bertrand A, Klifa C, Patriti S, Cippolini S, Lovera C, et al. Radiology workflow for RECIST assessment in clinical trials: can we reconcile time-efficiency and quality? Eur J Radio. 2019;118:257\u201363.","journal-title":"Eur J Radio"},{"key":"131_CR18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.radi.2017.08.002","volume":"24","author":"SE Thom","year":"2018","unstructured":"Thom SE. Does advanced practice in radiography benefit the healthcare system? A literature review. Radiography. 2018;24:84\u201389.","journal-title":"Radiography"},{"key":"131_CR19","unstructured":"The Society of Radiographers, \u2018The Scope of Practice 2013, March 2013, The Scope of Practice 2013. (sor.org)"}],"container-title":["BJC Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00131-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00131-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00131-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:46:39Z","timestamp":1743122799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00131-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["131"],"URL":"https:\/\/doi.org\/10.1038\/s44276-025-00131-8","relation":{},"ISSN":["2731-9377"],"issn-type":[{"value":"2731-9377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"30 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Institutional Review Board approval was not required as the study was a voluntary survey among health professionals regarding their professional responsibility, not related to any specific health information (The NHS Health Research Authority, HRA Algorithm, ). All data was handled anonymously. No vulnerable individuals participated in the survey. Participants were aware that the data would be collated anonymously for analysis and dissemination.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The aims of our survey were explained to the healthcare professionals before volunteering to complete the survey. Informed consent was fulfilled by agreeing to participate in the survey.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"19"}}